Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Journal for ImmunoTherapy of Cancer

Miguel Martin¹  Andrew Weickhardt²  Nidhi Patel³  Daniel Gusenleitner⁴  Richard D Carvajal⁵  Taito Esaki⁶  Patrick Schöffski⁷  Jürgen Krauß⁸  Amy Prawira⁹  Tian Zhang^1,10  David S Hong^1,11  Wallace Akerley^1,12  Filippo de Braud^1,13  John Sarantopoulos^1,14  Rina Hui^1,15  Chrisann Kyi^1,16  Daniel S W Tan^1,17  Ross A Soo^1,18  Padmaja Yerramilli-Rao^1,19  Vasileios Askoxylakis^1,19  Radha Ramesh^1,19  Ana Carion^1,19  Catherine A Sabatos-Peyton^1,19  Allen Lau^1,19  Eunice L Kwak^1,19  Tyler Longmire^1,19  Tiancen Hu^1,19  Tanay S Samant^1,19  Niladri Roy Chowdhury^1,19  Michela Maur^2,20  Barbara Deschler-Baier^2,21  María Ochoa-de-Olza^2,22 

[1] 1 Medical Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain;10Olivia Newton-John Cancer Wellness and Res, Heidelberg, VT, Australia;3 MS3, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA;Aff2 0000 0001 2106 9910grid.65499.37Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School Boston MA USA;Columbia University Irving Medical Center, New York City, New York, USA;Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium;Department of Medical Oncology, National Center of Tumor Diseases, Heidelberg, Baden-Württemberg, Germany;Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent’s Hospital, Sidney, New South Wales, Australia;Department of Medicine, Center for Prostate & Urologic Cancers, Duke Cancer Institute, Durham, North Carolina, USA;Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA;Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA;Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, Texas, USA;Medical Oncology, Westmead Hospital, Westmead, New South Wales, Australia;Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;National Cancer Centre Singapore, Singapore;National University Cancer Institute, Singapore;Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA;Oncologia Medica, AOU Policlinico di Modena, Modena, Emilia-Romagna, Italy;Universitätsklinikum Würzburg, Wurzburg, Germany;Vall d`Hebron University Hospital, Barcelona, Spain;

DOI  :  10.1136/jitc-2021-003776

来源: DOAJ

【 授权许可】

Unknown